<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">BUHMEIDA, ABDELBASET</style></author><author><style face="normal" font="default" size="100%">RISTAMÄKI, RAIJA</style></author><author><style face="normal" font="default" size="100%">LAMLUM, HANAN</style></author><author><style face="normal" font="default" size="100%">BENDARDAF, RIYAD</style></author><author><style face="normal" font="default" size="100%">HEIKKILÄ, SUVI</style></author><author><style face="normal" font="default" size="100%">COLLAN, YRJÖ</style></author><author><style face="normal" font="default" size="100%">SYRJÄNEN, KARI</style></author><author><style face="normal" font="default" size="100%">PYRHÖNEN, SEPPO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Nuclear Area is a Prognostic Determinant in Advanced Colorectal Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3083-3088</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The prognostic value of morphometric nuclear features in Dukes' Stages B/C and D colorectal cancer (CRC) was assessed. Patients and Methods: Primary tumours from 86 CRC patients were analysed, using an image overlay drawing system (Prodit Morphometry Program), for the following nuclear features: area, perimeter, diameter, form factor, roundness. Results: The median nuclear area (NA) was 104.6 μm2 (range 57.2 - 237.2 μm2). The NA was larger in patients with lymph node metastasis (p&lt;0.02). Altogether, 43% of the patients showed clinical response to irinotecan-based chemotherapy. All six patients with complete response (CR) had a NA above the median (p&lt;0.03). The disease-specific survival of the patients with a NA above the median was significantly better than in patients with smaller NA (p&lt;0.02). Conclusion: Using the median NA as the cut-off value seems to effectively discriminate patients who are likely to respond to irinotecan-based chemotherapy (with improved prognosis) from those who are non-responsive and develop progressive disease. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>